What is happening. Coenzyme Q10 (ubiquinone) is sometimes used by patients on lipid-lowering therapy because of concerns about statin-associated muscle symptoms. Evolocumab is a PCSK9 inhibitor monoclonal antibody and, unlike statins, does not deplete the mevalonate pathway and is not associated with myopathy or reductions in endogenous CoQ10. There is no pharmacokinetic interaction between CoQ10 and evolocumab. Co-use is benign, but CoQ10 should not be expected to add meaningful LDL-lowering or to mitigate a side effect that evolocumab does not cause.
Mechanism. No shared metabolic or pharmacokinetic pathway. Evolocumab is a subcutaneously injected monoclonal antibody cleared by proteolysis and target-mediated disposition (binding to PCSK9), not by CYP enzymes or hepatic transporters; CoQ10 is absorbed enterally and used in mitochondrial electron transport. The two do not interact.
Recommendation. No interaction-based restriction. CoQ10 may be continued if a patient takes it, but it is not required with evolocumab and does not address any evolocumab-specific risk. Do not substitute CoQ10 for evidence-based LDL-lowering therapy.